Dr. Reidy-Lagunes on FDA Approval of Telotristat Ethyl for Carcinoid Syndrome

Diane Reidy-Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of telotristat ethyl (Xermelo) as a treatment for carcinoid syndrome in patients with metastatic neuroendocrine tumors (NETs).

Diane Reidy-Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of telotristat ethyl (Xermelo) as a treatment for carcinoid syndrome in patients with metastatic neuroendocrine tumors (NETs).

Related Content:

OncLive TV
Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer
Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC
Dr Weiss on the Role of Breast Imaging in Breast Cancer Treatment Decision-Making